HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
 Help
PTPI [NASD]
Petros Pharmaceuticals, Inc.
Healthcare | Drug Manufacturers - Specialty & Generic | USA
statements
Index- P/E- EPS (ttm)-0.82 Insider Own30.08% Shs Outstand20.68M Perf Week-17.57%
Market Cap15.67M Forward P/E- EPS next Y- Insider Trans10.63% Shs Float14.48M Perf Month-38.46%
Income-9.00M PEG- EPS next Q- Inst Own4.70% Short Float0.66% Perf Quarter-49.53%
Sales7.80M P/S2.01 EPS this Y61.10% Inst Trans-18.67% Short Ratio0.06 Perf Half Y-70.02%
Book/sh1.73 P/B0.41 EPS next Y- ROA- Target Price- Perf Year-78.01%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.65 - 5.20 Perf YTD-78.93%
Dividend- P/FCF- EPS past 5Y- ROI-50.80% 52W High-86.51% Beta-
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin79.50% 52W Low8.64% ATR0.13
Employees24 Current Ratio2.60 Sales Q/Q-39.00% Oper. Margin- RSI (14)27.02 Volatility13.09% 10.92%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.09 Prev Close0.68
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.64M Price0.70
Recom- SMA20-28.44% SMA50-39.49% SMA200-62.99% Volume151,070 Change3.01%
May-16-22 05:00PM  
Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
GlobeNewswire
May-03-22 09:23AM  
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Companys Novel Topical Investigational Treatment for Peyronies Disease Which Impacts More Than 1 in 10 Men in the US
GlobeNewswire +7.21%
Apr-27-22 09:25PM  
Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022
GlobeNewswire
09:00AM  
Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV
ACCESSWIRE
Apr-26-22 09:15AM  
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology
GlobeNewswire -10.24%
Apr-19-22 09:15AM  
Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)
GlobeNewswire +20.91%
Apr-01-22 07:00AM  
Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights
GlobeNewswire -6.41%
Mar-03-22 08:00AM  
Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference
GlobeNewswire
Feb-01-22 09:15AM  
Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health
PR Newswire
Jan-24-22 09:15AM  
Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ (avanafil) to the United States
PR Newswire +10.60%
Jan-18-22 09:20AM  
Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug STENDRA® (avanafil)
PR Newswire -11.45%
Jan-06-22 04:30PM  
Petros Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference and the Biotech Showcase 2022
PR Newswire
Jan-05-22 01:38PM  
Neville Rodie & Shaw Inc Buys Cleveland-Cliffs Inc, Palo Alto Networks Inc, Novo Nordisk ...
GuruFocus.com -9.15%
Dec-28-21 09:15AM  
Petros Pharmaceuticals Announces Closing of $7.5 Million Offering
PR Newswire +9.27%
Dec-22-21 09:10AM  
Petros Pharmaceuticals Announces $7.5 Million Offering
PR Newswire -18.34%
Dec-08-21 09:15AM  
Petros Pharmaceuticals Announces Positive Over-the-Counter (OTC) Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA® (avanafil)
PR Newswire +7.69%
Dec-02-21 12:00PM  
Petros Pharmaceuticals Announces Closing of $10 Million Offering
PR Newswire +10.68%
Nov-30-21 09:00AM  
Petros Pharmaceuticals Announces $10 Million Offering
PR Newswire -28.50%
Nov-15-21 04:30PM  
Petros Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
PR Newswire
Nov-11-21 09:15AM  
Petros Pharmaceuticals to Present at the Q4 Investor Summit Conference
PR Newswire
Nov-08-21 09:15AM  
Petros Pharmaceuticals Expands Program for Novel Investigational Non-Invasive Treatment Formulation for Peyronie's Disease
PR Newswire
Nov-03-21 09:16AM  
Petros Pharmaceuticals, Inc. Through Exclusive Marketing Agreement with Hims & Hers Health, Inc. Generates 476% Year-Over-Year Growth of STENDRA Tablet Sales
PR Newswire +64.57%
Oct-21-21 09:25AM  
Petros Pharmaceuticals to Participate at Upcoming Benzinga Conference and Interview Show
PR Newswire
Oct-19-21 09:25AM  
Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering
PR Newswire
Oct-14-21 09:00AM  
Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering
PR Newswire
Sep-23-21 08:30AM  
Petros Pharmaceuticals to Present at the Benzinga Healthcare Small Cap Conference
PR Newswire
Sep-10-21 08:30AM  
Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
PR Newswire
Aug-17-21 09:25AM  
Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Increase in Year Over Year Quarterly STENDRA® (avanafil) Net Sales
PR Newswire -7.75%
Aug-16-21 08:30AM  
Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
ACCESSWIRE -10.26%
Aug-12-21 08:00AM  
Petros Pharmaceuticals to Present at Two Upcoming August Conferences
PR Newswire
Aug-11-21 10:39AM  
Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit
Newsfile
Jul-27-21 09:25AM  
FDA Grants Meeting to Petros Pharmaceuticals to Discuss Label Expansion of Erectile Dysfunction Drug STENDRA®
PR Newswire
Jul-13-21 09:15AM  
Petros Pharmaceuticals Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment
PR Newswire
Jul-12-21 08:15AM  
Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021
PR Newswire
Jun-02-21 10:12AM  
Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021
PR Newswire
May-17-21 08:22AM  
Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase in Year-Over-Year STENDRA Net Sales
PR Newswire +5.74%
May-14-21 08:30AM  
Petros Pharmaceuticals to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021
PR Newswire
May-07-21 08:00AM  
Petros Pharmaceuticals to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
PR Newswire +5.59%
Mar-18-21 09:00AM  
Recently Published Research on Stendra®(avanafil) for Endothelial Function in Men with Erectile Dysfunction to Initiate Petros Pharmaceuticals' Plans for Expanded Labeling
PR Newswire
Feb-18-21 08:00AM  
Petros Pharmaceuticals Welcomes Dr. Mohit Khera to Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil)
PR Newswire -9.22%
Feb-04-21 08:30AM  
Petros Pharmaceuticals Establishes Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil)
PR Newswire
Jan-19-21 08:00AM  
Petros Pharmaceuticals to Participate in NobleCon17
GlobeNewswire
Dec-08-20 04:15PM  
Neurotrope, Inc. Completes Independent Spin-off of Neurotrope Bioscience, Inc. and is Renamed Synaptogenix, Inc.
PR Newswire
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHULMAN JOHN DDirectorDec 22Buy3.43145,773500,0015,703,544Jan 03 06:13 AM
SHULMAN JOHN DDirectorNov 29Buy3.00500,0001,500,0005,557,771Nov 30 02:49 PM
SHULMAN JOHN DDirectorOct 18Buy1.721,661,8072,849,9995,057,771Oct 21 08:47 AM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do Not Sell My Data • Privacy Settings
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.